Article
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
The New England journal of medicine - 16 Feb 2017
Mok Tony S, Wu Yi-Long, Ahn Myung-Ju, Garassino Marina C, Kim Hye R, Ramalingam Suresh S, Shepherd Frances A, He Yong, Akamatsu Hiroaki, Theelen Willemijn S M E, Lee Chee K, Sebastian Martin, Templeton Alison, Mann Helen, Marotti Marcelo, Ghiorghiu Serban, Papadimitrakopoulou Vassiliki A
Abstract excerpt
BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. METHODS: In this randomized, international, open-label, phase 3 trial, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.